{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:34:48Z","timestamp":1790634888851,"version":"4.1.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"ELAN Fund for Research and Teaching, Friederich-Alexander Universit\u00e4t, University of Erlangen-N\u00fcrnberg"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bbr.2014.07.025","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T01:02:24Z","timestamp":1406595744000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Serotonin in antipsychotic drugs action"],"prefix":"10.1016","volume":"277","author":[{"given":"Davide","family":"Amato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2014.07.025_bib0005","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.bbr.2014.07.025_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004850-199605002-00002","article-title":"Negative symptoms: diagnosis, treatment and prognosis","volume":"11","author":"Buchanan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0020","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/schbul\/sbi035","article-title":"Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy","volume":"31","author":"Greenwood","year":"2005","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bbr.2014.07.025_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1749-6632.2011.06216.x","article-title":"Advancing drug discovery for schizophrenia","volume":"1236","author":"Marder","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0030","first-page":"390","article-title":"The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs","volume":"25","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.bbr.2014.07.025_bib0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","article-title":"Targeting the dopamine d2 receptor in schizophrenia","volume":"10","author":"Seeman","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bbr.2014.07.025_bib0040","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1073\/pnas.73.12.4354","article-title":"Dopamine receptors in human and calf brains, using [3h]apomorphine and an antipsychotic drug","volume":"73","author":"Seeman","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbr.2014.07.025_bib0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.bbr.2014.07.025_bib0050","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/468158a","article-title":"Schizophrenia the drug deadlock","volume":"468","author":"Abbott","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.07.025_bib0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0065","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-Ht2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"SUPPL 232","key":"10.1016\/j.bbr.2014.07.025_bib0075","first-page":"1","article-title":"Evidence for the existence of monoamine-containing neurons in the central nervous system I. Demonstration of monoamines in the cell bodies of brain stem neurons","author":"Dahlstroem","year":"1964","journal-title":"Acta Physiol Scand Suppl"},{"key":"10.1016\/j.bbr.2014.07.025_bib0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-Ht receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00337069","article-title":"Evidence for the existence of monoamine neurons in the central nervous system 3. The monoamine nerve terminal","volume":"65","author":"Fuxe","year":"1965","journal-title":"Z Zellforsch Mikrosk Anat"},{"key":"10.1016\/j.bbr.2014.07.025_bib0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.1990.70.2.513","article-title":"Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system","volume":"70","author":"Nicoll","year":"1990","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/syn.890210205","article-title":"Protein kinase C inhibitors enhance the 5-Ht2a receptor-mediated excitatory effects of serotonin on interneurons in rat piriform cortex","volume":"21","author":"Marek","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2014.07.025_bib0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1113\/jphysiol.1987.sp016862","article-title":"Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro","volume":"394","author":"Andrade","year":"1987","journal-title":"J Physiol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00177743","article-title":"Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus","volume":"336","author":"Andrade","year":"1987","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(91)90442-S","article-title":"Electrophysiology of the 5-Ht1a ligand Mdl 73005ef in the rat hippocampal slice","volume":"196","author":"Van den Hooff","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0125","first-page":"407","article-title":"Electrophysiological effects of way 100635, a New 5-Ht1a receptor antagonist, on dorsal raphe nucleus serotoninergic neurones and ca1 pyramidal cells in vitro","volume":"84","author":"Corradetti","year":"1996","journal-title":"Acta Physiol Hung"},{"key":"10.1016\/j.bbr.2014.07.025_bib0130","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(94)90289-5","article-title":"Way-100635 and Gr127935, effects on 5-hydroxytryptamine-containing neurones","volume":"271","author":"Craven","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0306-4522(95)00227-A","article-title":"Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat","volume":"69","author":"Hajos","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.07.025_bib0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/BF00170162","article-title":"Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine","volume":"351","author":"Hajos","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1476-5381.1995.tb15919.x","article-title":"Interaction between a selective 5-Ht1a receptor antagonist and an ssri in vivo: effects on 5-Ht cell firing and extracellular 5-Ht","volume":"115","author":"Gartside","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s002130050238","article-title":"Inhibition of 5-Ht cell firing in the Drn by non-selective 5-Ht reuptake inhibitors: studies on the role of 5-Ht1a autoreceptors and noradrenergic mechanisms","volume":"130","author":"Gartside","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0014-2999(88)90380-9","article-title":"Electrophysiological evidence for a functional differentiation between subtypes of the 5-Ht1 receptor","volume":"157","author":"Sinton","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0160","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/syn.890050206","article-title":"Differential responsiveness of the rat dorsal and median raphe 5-Ht systems to 5-Ht1 receptor agonists and P-chloroamphetamine","volume":"5","author":"Blier","year":"1990","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2014.07.025_bib0165","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1046\/j.1471-4159.1996.67051945.x","article-title":"Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways","volume":"67","author":"Casanovas","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.07.025_bib0170","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0022-3565(25)20965-X","article-title":"Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo","volume":"279","author":"Gartside","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0175","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0028-3908(94)90177-5","article-title":"The inhibitory effect of 8-Oh-Dpat on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex","volume":"33","author":"Ceci","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0180","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0022-3565(25)24515-3","article-title":"Are postsynaptic 5-Ht1a receptors involved in the anxiolytic effects of 5-Ht1a receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?","volume":"272","author":"Jolas","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0185","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.bjp.0702510","article-title":"Role of the medial prefrontal cortex in 5-Ht1a receptor-induced inhibition of 5-Ht neuronal activity in the rat","volume":"126","author":"Hajos","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/272168a0","article-title":"Serotonergic component of neuroleptic receptors","volume":"272","author":"Leysen","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.07.025_bib0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0026-895X(25)13812-1","article-title":"Multiple serotonin receptors: differential binding of [3h]5-hydroxytryptamine, [3h]lysergic acid diethylamide and [3h]Spiroperidol","volume":"16","author":"Peroutka","year":"1979","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(85)90857-1","article-title":"Quantitative autoradiographic mapping of serotonin receptors in the rat brain, Ii. serotonin-2 receptors","volume":"346","author":"Pazos","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0306-4522(87)90327-7","article-title":"Serotonin receptors in the human brain--Iv, autoradiographic mapping of serotonin-2 receptors","volume":"21","author":"Pazos","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.07.025_bib0210","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/PL00005075","article-title":"Selective visualization of rat brain 5-Ht2a receptors by autoradiography with [3h]Mdl 100,907","volume":"356","author":"Lopez-Gimenez","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0306-4522(93)90241-7","article-title":"Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain","volume":"54","author":"Morilak","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.07.025_bib0220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.npp.1380102","article-title":"Neurons expressing 5-Ht2 receptors in the rat brain: neurochemical identification of cell types by immunocytochemistry","volume":"11","author":"Morilak","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-Ht2 receptor family mrnas: comparison between 5-Ht2a and 5-Ht2c receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(95)00104-X","article-title":"The distribution of 5-Ht1a and 5-Ht2a receptor Mrna in human brain","volume":"676","author":"Burnet","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0235","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jnr.490350304","article-title":"Detection of 5-hydroxytryptamine2 receptors by radioligand binding, northern blot analysis, and Ca2+ responses in rat primary astrocyte cultures","volume":"35","author":"Deecher","year":"1993","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0240","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0022-3565(25)11149-X","article-title":"5-Hydroxytryptamine1a but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin","volume":"261","author":"Francis","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0245","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/cne.903510304","article-title":"Comparative localization of serotonin1a, 1c, and 2 receptor subtype Mrnas in rat brain","volume":"351","author":"Wright","year":"1995","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0006-8993(93)90747-B","article-title":"5-Ht2 receptor immunoreactivity on cholinergic neurons of the pontomesencephalic tegmentum shown by double immunofluorescence","volume":"627","author":"Morilak","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0255","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0006-8993(88)90172-2","article-title":"Correspondence between 5-Ht2 receptors and serotonergic axons in rat neocortex","volume":"453","author":"Blue","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0014-2999(91)90840-M","article-title":"The novel 5-Ht2 receptor antagonist, Rp 62203, selectively blocks serotoninergic but not dopaminergic-induced inhibition in the rat prefrontal cortex","volume":"204","author":"Godbout","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0028-3908(94)90059-0","article-title":"Molecular biology of 5-Ht receptors","volume":"33","author":"Boess","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0270","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1046\/j.1471-4159.1997.69041449.x","article-title":"The serotonin 5-Ht2c receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis","volume":"69","author":"Wolf","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.07.025_bib0275","first-page":"411","article-title":"Adaptive regulation of central serotonin receptors linked to phosphoinositide hydrolysis","volume":"3","author":"Sanders-Bush","year":"1990","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.bjp.0702145","article-title":"Comparative desensitization of the human 5-Ht2a and 5-Ht2c receptors expressed in the human neuroblastoma cell line Sh-Sy5y","volume":"125","author":"Briddon","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0285","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0922-4106(91)90093-W","article-title":"Chronic mianserin treatment decreases 5-Ht2 receptor binding without altering 5-Ht2 receptor Mrna levels","volume":"207","author":"Roth","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0290","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1749-6632.1998.tb10184.x","article-title":"Creation of a constitutively activated state of the 5-Ht2a receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists","volume":"861","author":"Egan","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0295","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1989.sp017786","article-title":"5-Hydroxytryptamine acts at 5-Ht2 receptors to decrease potassium conductance in rat nucleus accumbens neurones","volume":"417","author":"North","year":"1989","journal-title":"J Physiol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0305","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","article-title":"5-Hydroxytryptamine2 and 5-hydroxytryptamine 1a receptors mediate opposing responses on membrane excitability in rat association cortex","volume":"40","author":"Araneda","year":"1991","journal-title":"Neuroscience"},{"issue":"Pt 3","key":"10.1016\/j.bbr.2014.07.025_bib0310","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1113\/jphysiol.1994.sp020469","article-title":"Transient and long-lasting actions of 5-Ht on rat dentate gyrus neurones in vitro","volume":"481","author":"Piguet","year":"1994","journal-title":"J Physiol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0315","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-8993(84)91137-5","article-title":"Hyperpolarization of serotonergic neurons by serotonin and Lsd: studies in brain slices showing increased K+ conductance","volume":"305","author":"Aghajanian","year":"1984","journal-title":"Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0320","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.890090307","article-title":"Excitatory responses to serotonin (5-Ht) in neurons of the rat piriform cortex: evidence for mediation by 5-Ht1c receptors in pyramidal cells and 5-Ht2 receptors in interneurons","volume":"9","author":"Sheldon","year":"1991","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2014.07.025_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(94)90502-9","article-title":"Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by Mdl 100,907, a highly selective 5-Ht2a receptor antagonist","volume":"259","author":"Marek","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0330","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/0028-3908(91)90028-A","article-title":"Regulation of noradrenergic coerulean neuronal firing mediated by 5-Ht2 receptors: involvement of the prepositus hypoglossal nucleus","volume":"30","author":"Gorea","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-0186(91)90029-D","article-title":"Autoradiography of serotonin receptor subtypes in the central nervous system","volume":"18","author":"Radja","year":"1991","journal-title":"Neurochem Int"},{"key":"10.1016\/j.bbr.2014.07.025_bib0340","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0306-4522(95)00283-O","article-title":"Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2c receptors","volume":"69","author":"Rick","year":"1995","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.07.025_bib0345","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-6147(00)88991-9","article-title":"5-Ht2 receptor subtypes: a family re-united?","volume":"16","author":"Baxter","year":"1995","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0350","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"Rs-102221: a novel high affinity and selective, 5-Ht2c receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0355","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"Sb 242084, a selective and brain penetrant 5-Ht2c receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0360","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0022-3565(25)22189-9","article-title":"Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis","volume":"246","author":"Sanders-Bush","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0365","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.3399891","article-title":"Molecular characterization of a functional Cdna encoding the serotonin 1c receptor","volume":"241","author":"Julius","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bbr.2014.07.025_bib0370","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.1016\/S0021-9258(17)32625-X","article-title":"Constitutively active 5-hydroxytryptamine2c receptors reveal novel inverse agonist activity of receptor ligands","volume":"269","author":"Barker","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bbr.2014.07.025_bib0375","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.124.3212.121","article-title":"Some serotoninlike activities of lysergic acid diethylamide","volume":"124","author":"Shaw","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.bbr.2014.07.025_bib0380","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF00402364","article-title":"Special antagonism of amphetamine-induced abnormal behaviour, inhibition of stereotyped activity with increase of some normal activities","volume":"7","author":"Randrup","year":"1965","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.bbr.2014.07.025_bib0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-3956(74)90070-3","article-title":"Antipsychotic drugs and catecholamine synapses","volume":"11","author":"Carlsson","year":"1974","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0022-3956(74)90066-1","article-title":"Stereoselective features of catecholamine dispostion and their behavioral implications","volume":"11","author":"Snyder","year":"1974","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0395","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2014.07.025_bib0400","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1001\/archpsyc.1979.01780090013001","article-title":"Neurotransmitter receptors in frontal cortex of schizophrenics","volume":"36","author":"Bennett","year":"1979","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archgenpsychiatry.2009.176","article-title":"Decreased frontal serotonin2a receptor binding in antipsychotic-naive patients with first-episode schizophrenia","volume":"67","author":"Rasmussen","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0410","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","article-title":"Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders","volume":"174","author":"Roth","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0415","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0420","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","article-title":"Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis","volume":"172","author":"Kuroki","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0425","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00213-008-1226-4","article-title":"Modulation of striatal dopamine release by 5-Ht2a and 5-Ht2c receptor antagonists: [11c]Raclopride pet studies in the rat","volume":"200","author":"Egerton","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl 1","key":"10.1016\/j.bbr.2014.07.025_bib0430","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1055\/s-2007-992133","article-title":"Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action","volume":"40","author":"Di Pietro","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0435","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.286.5437.105","article-title":"Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by Alpha2 adrenoceptor blockade","volume":"286","author":"Hertel","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bbr.2014.07.025_bib0440","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0924-977X(00)00087-0","article-title":"The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus","volume":"10","author":"Antoniou","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0445","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0450","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0455","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2005.06.035","article-title":"Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex","volume":"387","author":"Zocchi","year":"2005","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.07.025_bib0460","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-007-0698-y","article-title":"In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain","volume":"191","author":"Bortolozzi","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0465","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00213-010-2065-7","article-title":"Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex","volume":"214","author":"Carli","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0470","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1017\/S1461145711000010","article-title":"Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment","volume":"14","author":"Amato","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0475","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejphar.2005.05.004","article-title":"Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex","volume":"516","author":"Amargos-Bosch","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0480","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1471-4159.2003.02044.x","article-title":"Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs","volume":"87","author":"Amargos-Bosch","year":"2003","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.07.025_bib0485","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1471-4159.2007.04532.x","article-title":"Antipsychotic drugs reverse the ampa receptor-stimulated release of 5-Ht in the medial prefrontal cortex","volume":"102","author":"Amargos-Bosch","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.07.025_bib0490","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(97)01207-7","article-title":"5-Ht1a receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine","volume":"334","author":"Assie","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0495","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-hydroxytryptamine 1a receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assie","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0500","doi-asserted-by":"crossref","unstructured":"Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-Ht) and Da D antagonism and 5-Ht partial agonism. J Neurochem 2013, http:\/\/dx.doi.org\/10.1111\/jnc.12512.","DOI":"10.1111\/jnc.12512"},{"key":"10.1016\/j.bbr.2014.07.025_bib0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejphar.2010.11.023","article-title":"Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex","volume":"653","author":"Ohoyama","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0510","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00213-004-1880-0","article-title":"Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine","volume":"176","author":"Denys","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0515","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuropharm.2003.09.001","article-title":"Brain region and dose effects of an olanzapine\/fluoxetine combination on extracellular monoamine concentrations in the rat","volume":"46","author":"Koch","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0520","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0893-133X(00)00119-6","article-title":"Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex","volume":"23","author":"Zhang","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S1461145705005900","article-title":"Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine","volume":"9","author":"Amargos-Bosch","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0530","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0304-3940(95)11338-W","article-title":"Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism","volume":"187","author":"Ferre","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.07.025_bib0535","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/sj.npp.1301356","article-title":"Clozapine and haloperidol differently suppress the Mk-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat","volume":"32","author":"Lopez-Gil","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0540","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0893-133X(97)00002-X","article-title":"Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism","volume":"17","author":"Hertel","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0545","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0550","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0014-2999(99)00491-4","article-title":"The 5ht(1a) receptor ligand, S15535, antagonises G-protein activation: a [35s]Gtpgammas and [3h]S15535 autoradiography study","volume":"384","author":"Newman-Tancredi","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0555","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-Hydroxytryptamine2a receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0560","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-Ht1a receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0565","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-Ht1a agonist, as a putative mediator of quetiapine's antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0570","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics?. A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0575","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0580","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0269881108089586","article-title":"Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour","volume":"23","author":"Dahan","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0585","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (Sm-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0590","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/0306-3623(95)00077-1","article-title":"Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain","volume":"26","author":"Tanaka","year":"1995","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0595","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-Ht7) and 5-Ht1a receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0600","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","article-title":"Agonist and antagonist actions of antipsychotic agents at 5-Ht1a receptors: a [35s]Gtpgammas binding study","volume":"355","author":"Newman-Tancredi","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0605","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0014-2999(01)01493-5","article-title":"Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-Ht(1a) receptors expressed in hela cells","volume":"433","author":"Cosi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0610","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0893-133X(95)00049-J","article-title":"Differential regulation of rat 5-Ht2a and 5-Ht2c receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs","volume":"13","author":"Kuoppamaki","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0615","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0920-9964(91)90030-U","article-title":"Mechanisms of action of atypical antipsychotic drugs, implications for novel therapeutic strategies for schizophrenia","volume":"4","author":"Deutch","year":"1991","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0620","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-3565(24)37560-3","article-title":"Creation of a constitutively activated state of the 5-hydroxytryptamine2a receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs","volume":"286","author":"Egan","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0625","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-6997(25)06671-2","article-title":"Effects of antipsychotic drugs on serotonin receptors","volume":"43","author":"Meltzer","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0630","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5ht2a and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0635","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0640","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/BF02245006","article-title":"Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5ht2 receptors","volume":"112","author":"Leysen","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0645","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0650","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/NDT.S34433","article-title":"Profile of blonanserin for the treatment of schizophrenia","volume":"9","author":"Tenjin","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.bbr.2014.07.025_bib0655","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2c receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0660","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","article-title":"Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2c) receptor","volume":"299","author":"Rauser","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0665","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (Sm-13496), a novel atypical antipsychotic drug, reverses Mk-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0670","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/0269881113478281","article-title":"Comparison of the anti-dopamine D(2) and anti-serotonin 5-Ht(2a) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof","volume":"27","author":"Suzuki","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0675","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.bjp.0701561","article-title":"Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine","volume":"122","author":"Hertel","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0680","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1a, 2a and 2c receptors in rat forebrain regions","volume":"161","author":"Tarazi","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0685","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1a and serotonin2a receptors in pyramidal and gabaergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.bbr.2014.07.025_bib0690","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0304-3940(01)02208-X","article-title":"5-Ht(2a) Receptor-like protein is present in small neurons located in rat mesopontine cholinergic nuclei, but absent from cholinergic neurons","volume":"314","author":"Fay","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.07.025_bib0695","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1523\/JNEUROSCI.17-02-00625.1997","article-title":"Bicuculline and gabazine are allosteric inhibitors of channel opening of the gabaa receptor","volume":"17","author":"Ueno","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0700","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0022-3565(25)12836-X","article-title":"Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization","volume":"277","author":"Iyer","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bbr.2014.07.025_bib0705","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1523\/JNEUROSCI.22-07-02843.2002","article-title":"The physiological role of 5-Ht2a receptors in working memory","volume":"22","author":"Williams","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0710","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/00207450490430552","article-title":"Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5ht-2a receptors?","volume":"114","author":"Tyson","year":"2004","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.bbr.2014.07.025_bib0715","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0920-9964(89)90034-0","article-title":"The efficacy of the D2 and 5-Ht2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis, an open dose-finding study","volume":"2","author":"Castelao","year":"1989","journal-title":"Schizophr Res"},{"key":"10.1016\/j.bbr.2014.07.025_bib0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10673229809000313","article-title":"Negative symptoms in schizophrenia: neurobiological models and treatment response","volume":"6","author":"Goff","year":"1998","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0725","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004850-200303000-00004","article-title":"The onset and time course of response of negative symptoms to add-on fluvoxamine treatment","volume":"18","author":"Silver","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0730","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00004714-199806000-00005","article-title":"Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study","volume":"18","author":"Silver","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0735","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","article-title":"Fluvoxamine as an adjunctive agent in schizophrenia","volume":"7","author":"Silver","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.bbr.2014.07.025_bib0740","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1176\/ajp.156.2.335","article-title":"Risperidone for exclusively negative symptoms","volume":"156","author":"Lane","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0745","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/0269881107082119","article-title":"Long-acting risperidone improves negative symptoms in stable psychotic patients","volume":"22","author":"Curtis","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0750","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0755","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbr.2014.07.025_bib0760","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0006-3223(99)00271-1","article-title":"Neurobiology of the obsessive-compulsive spectrum disorders","volume":"47","author":"Stein","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0765","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-3223(87)90199-5","article-title":"Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology","volume":"22","author":"Zohar","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0770","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2165\/00003495-199243020-00007","article-title":"Current concepts in the pharmacological treatment of obsessive-compulsive disorder","volume":"43","author":"Zohar","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.bbr.2014.07.025_bib0775","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1192\/S0007125000297857","article-title":"Role of serotonin in obsessive-compulsive disorder","author":"Baumgarten","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.bbr.2014.07.025_bib0780","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.mp.4001365","article-title":"Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype","volume":"8","author":"Ozaki","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0785","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bbr.2014.07.025_bib0790","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.schbul.a033375","article-title":"Risperidone versus haloperidol on secondary memory: can newer medications aid learning?","volume":"25","author":"Kern","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bbr.2014.07.025_bib0795","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/schbul\/sbq040","article-title":"Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia","volume":"37","author":"Piontkewitz","year":"2011","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.bbr.2014.07.025_bib0800","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JCP.0b013e31827b97a6","article-title":"Effects of aripiprazole, risperidone, and olanzapine on 5-ht1a receptors in patients with schizophrenia","volume":"33","author":"Lerond","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0805","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mp.2012.78","article-title":"Measuring endogenous changes in serotonergic neurotransmission in humans: a [11c]Cumi-101 pet challenge study","volume":"17","author":"Selvaraj","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0810","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0028-3908(01)00034-X","article-title":"Acute increases in monoamine release in the rat prefrontal cortex by the Mglu2\/3 agonist Ly379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade","volume":"40","author":"Cartmell","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0815","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0028-3908(98)00017-3","article-title":"The role of 5-Ht1a autoreceptors and alpha1-adrenoceptors in the modulation of 5-Ht release--Iii. clozapine and the novel putative antipsychotic S 16924","volume":"37","author":"Bengtsson","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0820","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00213-005-0206-1","article-title":"Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex","volume":"185","author":"Huang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0825","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF02245607","article-title":"Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain","volume":"124","author":"Hertel","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0830","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0278-5846(98)00042-6","article-title":"Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action","volume":"22","author":"Hertel","year":"1998","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.bbr.2014.07.025_bib0835","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0028-3908(99)00045-3","article-title":"The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex","volume":"38","author":"Hertel","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2014.07.025_bib0840","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S1734-1140(13)71472-5","article-title":"Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex","volume":"65","author":"Kaminska","year":"2013","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.bbr.2014.07.025_bib0845","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002130000582","article-title":"Receptor-mediated regulation of serotonin output in the rat dorsal raphe nucleus: effects of risperidone","volume":"153","author":"Hertel","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2014.07.025_bib0850","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0014-2999(92)90731-I","article-title":"Clozapine has sub-micromolar affinity for 5-Ht1a receptors in human brain tissue","volume":"221","author":"Mason","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0855","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90267-L","article-title":"Biphasic displacement of [3h]Ym-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics","volume":"237","author":"Assie","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0860","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(89)90516-5","article-title":"Comparison of [3h]Ym-09151-2 with [3h]Spiperone and [3h]Raclopride for dopamine d-2 receptor binding to rat striatum","volume":"173","author":"Terai","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bbr.2014.07.025_bib0865","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1006\/bbrc.1999.0220","article-title":"Dopamine D4-like binding sites labeled by [3h]nemonapride include substantial serotonin 5-Ht2a receptors in primate cerebral cortex","volume":"255","author":"Noda-Saita","year":"1999","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814004744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432814004744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:47:23Z","timestamp":1746316043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432814004744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":173,"alternative-id":["S0166432814004744"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.07.025","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotonin in antipsychotic drugs action","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}